Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study

Boormans, J. L.; De Wit, R.; Kamat, A.; Uchio, E.; Mourey, L.; Krieger, L.; Singer, E. A.; Grivas, P.; Seo, H. K.; Nishiyama, H.; Konety, B.; Nam, K.; Kapadia, E.; Frenkl, T.; Kulkarini, G. S.; Bajorin, D.; Balar, Arjun V.

Published in

Elsevier, European Urology Supplements, 1(18), p. e758-e759, 2019

DOI: 10.1016/s1569-9056(19)30557-3

Tools

Export citation

Search in Google Scholar

Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study

Journal article published in 2019 by J. L. Boormans, R. De Wit, A. Kamat, E. Uchio, L. Mourey, L. Krieger, E. A. Singer, P. Grivas, H. K. Seo, H. Nishiyama, B. Konety, K. Nam, E. Kapadia, T. Frenkl, G. S. Kulkarini and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study